Durham, Benjamin H.
Lopez Rodrigo, Estibaliz
Picarsic, Jennifer http://orcid.org/0000-0002-3718-6422
Abramson, David
Rotemberg, Veronica
De Munck, Steven
Pannecoucke, Erwin
Lu, Sydney X.
Pastore, Alessandro http://orcid.org/0000-0002-3621-4807
Yoshimi, Akihide http://orcid.org/0000-0002-0664-7281
Mandelker, Diana
Ceyhan-Birsoy, Ozge
Ulaner, Gary A.
Walsh, Michael
Yabe, Mariko
Petrova-Drus, Kseniya
Arcila, Maria E.
Ladanyi, Marc
Solit, David B. http://orcid.org/0000-0002-6614-802X
Berger, Michael F.
Hyman, David M. http://orcid.org/0000-0001-8150-9762
Lacouture, Mario E.
Erickson, Caroline
Saganty, Ruth
Ki, Michelle
Dunkel, Ira J. http://orcid.org/0000-0001-8091-6067
Santa-María López, Vicente
Mora, Jaume http://orcid.org/0000-0002-9386-5980
Haroche, Julien
Emile, Jean-Francois http://orcid.org/0000-0002-6073-4466
Decaux, Olivier
Geissmann, Frederic
Savvides, Savvas N.
Drilon, Alexander http://orcid.org/0000-0001-6806-9061
Diamond, Eli L. http://orcid.org/0000-0001-5456-5961
Abdel-Wahab, Omar http://orcid.org/0000-0002-3907-6171
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1 R01 CA201247, K08 CA218901)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 28 May 2019
Accepted: 17 October 2019
First Online: 25 November 2019
Competing interests
: The authors declare the following competing interests. G.A.U. received personal fees from Sanofi and grants from Sanofi, Novartis and Genentech. M.L. received advisory board compensation from Merck, AstraZeneca, Bristol–Myers Squibb, Takeda and Bayer and research support from Loxo Oncology and Helsinn Healthcare. D.B.S. served as a consultant and received honoraria from Pfizer, Loxo Oncology, Lilly Oncology, Vivideon Therapeutics and Illumina and stock options from Loxo Oncology. M.F.B. received personal fees from Roche and research support from Illumina. D.M.H. received personal fees from Atara Biotherapeutics, Chugai Pharma, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer, Debiopharm Group and Genentech and grants from the National Cancer Institute, AstraZeneca, Puma Biotechnology and Loxo Oncology. I.D. served as a consultant for Apexigen, Bayer and Celgene and received research support from Bristol–Myers Squibb and Novartis. M.E.L. received personal fees from Loxo Oncology, AstraZeneca, Roche/Genentech and Novartis. A.D. received research funding from Foundation Medicine and personal fees from Ignyta/Genentech/Roche, Loxo/Bayer/Lilly, Takeda/Ariad/Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutics, Exelixis, Tyra Biosciences, Verastem and MORE Health. O.A.-W. received grants from H3B Biomedicine and personal fees from H3B Biomedicine, Foundation Medicine, Merck and Jansen unrelated to this manuscript. The remaining authors have nothing to disclose.